Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables - Other: 2016-2018

Historic Receivables - Other for Adma Biologics (ADMA) over the last 2 years, with Dec 2018 value amounting to $961,145.

  • Adma Biologics' Receivables - Other fell 22.84% to $961,145 in Q4 2018 from the same period last year, while for Dec 2018 it was $961,145, marking a year-over-year decrease of 22.84%. This contributed to the annual value of $961,145 for FY2018, which is 22.84% down from last year.
  • As of Q4 2018, Adma Biologics' Receivables - Other stood at $961,145, which was down 4.46% from $1.0 million recorded in Q3 2018.
  • Adma Biologics' Receivables - Other's 5-year high stood at $1.2 million during Q4 2017, with a 5-year trough of $726,409 in Q1 2018.
  • Its 3-year average for Receivables - Other is $1.0 million, with a median of $987,823 in 2016.
  • Its Receivables - Other has fluctuated over the past 5 years, first climbed by 28.46% in 2017, then dropped by 22.84% in 2018.
  • Quarterly analysis of 3 years shows Adma Biologics' Receivables - Other stood at $969,675 in 2016, then grew by 28.46% to $1.2 million in 2017, then decreased by 22.84% to $961,145 in 2018.
  • Its last three reported values are $961,145 in Q4 2018, $1.0 million for Q3 2018, and $1.0 million during Q2 2018.